Medtronic acquire neurovascular device company Scientia Vascular for $550 million, expanding its portfolio with guidewires and catheters.
GlobalData on MSN
J&J reports positive data for Erda-iDRS in bladder cancer
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
Access GPO has entered a multi-year agreement with Medtronic to expand ASC access to the Affera mapping and ablation system ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
Zacks Investment Research on MSN
JNJ's bladder cancer therapy meets key goal in early-stage study
Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical ...
The prospective, multicenter phase 2 RACE-IT trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results